FDA warned Dr. Robert J. Hayashi over protocol deviations in pediatric drug trials that exposed a child to unnecessary study drug and invasive procedures.
What happened
FDA inspected the clinical site from June 23, 2022, to July 8, 2022, as part of its Bioresearch Monitoring Program. FDA found the investigator did not follow the investigational plan for two protocols: a 5-year-old subject received study drug during the final two maintenance cycles when it should have been omitted, and the only enrolled subject in another protocol received a 3-day study drug course without a required eligibility check.
What FDA found
FDA said the investigator gave a 5-year-old subject a study drug dose during the last two maintenance cycles even though the protocol required omitting it, leading to lumbar punctures and anesthesia.
21 CFR 312.60FDA said the investigator gave a 3-day course of a study drug without the required treatment eligibility criterion before starting it.
21 CFR 312.60
What FDA wants
Within 15 business days, notify FDA in writing of actions taken to prevent similar violations. FDA also asks for documentation that mandatory training occurred and an explanation of how it will ensure compliant ongoing and future trials.
Who should pay attention
- clinical trial sponsors and principal investigators
- sites enrolling pediatric patients in investigator-initiated trials
- IRBs and research quality teams overseeing IND studies
This is a summary. Read the original letter on fda.gov.